• Home
  • Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Author List
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA
Publication
British journal of cancer
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1442979
Publication Year
2005
PubMed ID
15999098
Publication Title
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9.